Novo Nordisk vs Structure Therapeutics: Revenue Comparison
Novo Nordisk (NVO) and Structure Therapeutics (GPCR) are peers in GLP-1. Novo Nordisk reported revenue of $96.8B as of Q1 2026, compared with $0 for Structure Therapeutics. Novo Nordisk leads on revenue.
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q1 2026: Novo Nordisk 96.823, Structure Therapeutics 0.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Novo Nordisk, Structure Therapeutics.| Metric | Novo Nordisk | Structure Therapeutics |
|---|---|---|
| Market Cap | - | - |
| Revenue | $96.82B | $0 |
| Cost of Revenue | $13.60B | $1.00M |
| Gross Profit | $83.22B | $-1.00M |
| Operating Income | $59.62B | $-90.00M |
| Net Income | $48.56B | $-76.00M |
| R&D Expense | $10.28B | $67.00M |
| Earnings Per Share | $10.91 | -$1.05 |
| Gross Margin | 86.0% | - |
| Operating Margin | 61.6% | - |
| Net Profit Margin | 50.1% | - |
| Free Cash Flow | $12.04B | $14.00M |
| Cumulative Free Cash Flow | $654.97B | $-469.00M |
| Operating Cash Flow | $24.08B | $15.00M |
| Cash & Equivalents | $21.13B | $316.00M |